<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263298</url>
  </required_header>
  <id_info>
    <org_study_id>SYS-C-201801-5010</org_study_id>
    <nct_id>NCT04263298</nct_id>
  </id_info>
  <brief_title>Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herui Yao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial aims to compare the progression free survival (PFS) and safety of
      fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in
      hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic breast cancer (MBC) is incurable. Although first-line endocrine therapy is
      preferred to hormone receptor positive (HR+), human epidermal growth factor receptor-2
      negative (HER2-) MBC, combination chemotherapy should be reserved as the initial treatment
      for patients with rapid clinical progression, life-threatening visceral metastases, and need
      for rapidly symptom control. Either prolonged chemotherapy or endocrine therapy may be used
      as maintenance after disease control. However, which maintenance strategy is superior in
      terms of delaying disease progression as well as maintaining quality of life (QOL) remains
      uncertain. This phase III trial aims to compare the efficacy and safety of fulvestrant or
      capecitabine as maintenance therapy after first-line combined chemotherapy in HR+/HER2- MBC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Estimated 18 months</time_frame>
    <description>From enrollment to progression or death (for any reason)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Estimated 60 months</time_frame>
    <description>From enrollment to death (for any reason)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Estimated 18 months</time_frame>
    <description>Ratio of CR and PR in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Estimated 18 months</time_frame>
    <description>Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life (QOL)</measure>
    <time_frame>Estimated up to 60 months</time_frame>
    <description>All patients need to fill in the Functional Assessment of Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure multidimensional quality of life (QL) in patients with breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>From informed consent through 28 days following treatment completion</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Fulvestrant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant 500mg Days 0, 14, 28, then every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant 500mg Days 0, 14, 28, then every 28 days</description>
    <arm_group_label>Fulvestrant Group</arm_group_label>
    <other_name>Experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine Oral Product</intervention_name>
    <description>Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off</description>
    <arm_group_label>Capecitabine Group</arm_group_label>
    <other_name>Active Comparator control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female patients with advanced breast cancer diagnosed by pathology (aged 18-70,
             including 18 and 70 years old), not suitable for surgical resection or radiation
             therapy for the purpose of cure;

          -  Pathological examination confirmed ER and / or PR positive, HER-2 negative (Positive
             ER expression: immunohistochemistry &gt;1% tumor cell staining; Positive PR expression:
             immunohistochemistry &gt;1% tumor cell staining; HER-2 negative: immunohistochemistry is
             0,1+, or FISH/CISH negative when immunohistochemistry is 2+);

          -  Patients with advanced breast cancer who have no disease progression after a
             4-8-course first-line chemotherapy regimen (the effect is evaluated as complete
             response/ partial response/ stable disease)

          -  WHO physical status 0-1 points, estimated lifetime at least 3 months;

          -  Imaging examinations within 3 weeks before enrollment were required for assessing
             tumor lesions before maintenance treatment (Examination results from local Tertiary A
             hospital are available);

          -  Previous treatment-related toxicity should be relieved to ≤ Grade 1 according to NCI
             CTCAE (version 4.03) before randomization (Except for hair loss and other toxicities
             that are not at risk to the patient's safety based on the investigator's judgment);

          -  The routine blood test was normal within 1 week before enrollment: WBC ≥3.0×10^9／L, b.
             ANC ≥1.5×10^9／L, c. PLT ≥100×10^9／L;

          -  The liver and kidney function test was normal within 1 week before enrollment (Take
             the normal value of the laboratory of each research center as the standard): a.
             TBIL≤1.5× Upper Limit of Normal (ULN)b. ALT/AST≤2.5×ULN（Liver metastasis patients
             ≤5xULN） c. Serum Cr ≤1.5×ULN, or Ccr ≥60 ml/min;

          -  Informed consent form signed before enrollment.

        Exclusion Criteria:

        Cannot be grouped if any of the following is true:

          -  Central nervous system metastasis (including brain parenchyma, pia mater, and
             meningeal metastasis)

          -  Diagnosis of any other malignant tumor within 3 years before randomization, except for
             adequately treated basal cells or squamous cell skin cancer or cervical cancer in
             situ;

          -  Endocrine therapy for advanced disease;

          -  Pregnant or breast-feeding patients;

          -  Patients with accompanying disease or situation that may interfere with the study, or
             any serious medical problems that may affect the safety of the subject (for example,
             uncontrolled heart disease or high blood pressure, active or uncontrolled infection,
             active hepatitis B virus infection);

          -  Patients who were unable to tolerate capecitabine toxicity were first identified in
             first-line treatment;

          -  Patients with recurrent metastatic disease within 2 years of adjuvant endocrine
             therapy (including 2 years);

          -  Patients with first-line capecitabine monotherapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herui Yao, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shusen Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kun Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qianjun Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruilian Xu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peijian Peng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fifth Subsidiary Sun Yat-sen University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Ling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Public Health Institute of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Herui Yao, PhD</last_name>
    <phone>+86 13500018020</phone>
    <email>yaoherui@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianjun Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Qianjun Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kun Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Public Health Institute of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ling, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herui Yao, PhD</last_name>
      <phone>+86 13500018020</phone>
      <email>yaoherui@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Herui Yao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Shusen Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruilian Xu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fifth Subsidiary Sun Yat-sen University Hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peijian Peng, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Herui Yao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

